Summary
The reversibility of cisplatin-protein interactions by the modulating agent WR2721, its active thiol-metabolite WR1065, and the symmetrical disulfide WR33278 was studied using the model compounds (Pt(diethylenetriammine) monofunctionally bound to the sulfur in glutathione (Pt(dien)SG) and Pt(diethylenetriammine) monofunctionally bound to the sulfur in S-methylglutathione (Pt(dien)SMeG). Both model compounds could be quantified by high-performance liquid chromatography (HPLC) with UV detection. The Pt-cysteine-like bond in Pt(dien)SG could not be reversed by any of the WR compounds or by the strong nucleophiles thiosulfate (TS) and diethyldithiocarbamate (DDTC). However, the Ptmethionine-like bond in Pt(dien)SMeG could be reversed by WR1065, although the reversal was slow (k2=0.142m −1 s−1) as compared with that obtained using the modulating agents TS (k2=10.1m −1 s−1) and DDTC (k2=3.66m −1 s−1). WR2721 was hardly able to reverse the Pt-S bond in Pt(dien)SMeG (k2=0.00529m −1 s−1), and WR33278 showed no capacity to do so. The activity ofcis-diamminedichloroplatinum(II) (CDDP)-inactivated fumarase was not appreciably restored by any of the WR compounds (16%, 7.7%, and 0 for 20mm WR1065, WR2721, and WR33278, respectively) in contrast to the strong nucleophile DDTC (61% for 2mm DDTC). These in vitro studies provide information at the molecular level that may explain why WR2721, in contrast to DDTC, does not provide protection against cisplatin-induced nephrotoxicity when it is given after platinum-containing chemotherapy. The results support the present clinical use of WR2721 prior to the administration of platinum compounds.
Similar content being viewed by others
References
Bodenner DL, Dedon PC, Keng PC, Borch RF (1986) Effect of dithiocarbamate oncis-diamminedichloroplatinum(II)-inducedcytotoxicity, DNA cross-linking, and y-glutamyl transpeptidase inhibition. Cancer Res 46: 2745
Boelrijk AEM, Boogaard PJ, Lempers ELM, Reedijk J (1991) Regeneration experiments of the platinated enzyme fumarase by sodium diethyldithiocarbamate, thiourea and sodium thiosulphate. J Inorg Biochem 41: 17
Borch RF, Pleasants ME (1979) Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate in a rat model. Proc Natl Acad Sci USA 76: 6611
Borch RF, Katz JC, Lieder PH, Pleasants ME (1980) Effect of diethyl-dithiocarbamate on tumor response to cis-platinum in a rat model. Proc Natl Acad Sci USA 77: 5441
Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC (1988) Uptake of WR2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634
Glover D, Fox KR, Weiler C, Kligerman MM, Turrisi A, Glick JH (1988) Clinical trials of WR-2721 prior to alkylating agent chemotherapy and radiotherapy. Pharmacol Ther 39: 3
Goel R, Cleary SM, Horton C, Kirmani S, Abramson IS, Kelly C, Howell SB (1989) Effect of sodium thiosulphate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 81: 1552
Lempers ELM, Reedijk J (1990) Reversibility of binding of cisplatin-methionine in proteins by diethyldithiocarbamate or thiourea: a study with model adducts. Inorg Chem 29: 217
Ozols RF (1989) Cisplatin dose intensity. Semin Oncol 16: 22
Quazi R, Chang AYC, Borch RF, Montine T, Dedon PC, Loughner J, Bennett JM (1988) Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a chemoprotector from toxic effects of cisplatin. J Natl Cancer Inst 80: 1486
Racker E (1950) Spectrophotometric measurement of the enzymic formation of fumaric andcis-acetonic acids. Biochim Biophys Acta 4: 211
Shaw LM, Glover D, Turrisi A, Brown DQ, Bonner HS, Norfleet AL, Weiler C, Glick JH, Kligerman MM (1988) WR2721 pharmacokinetics. Pharmacol Ther 39: 195
Sundquist WI, Lippard SJ (1990) The coordination chemistry of platinum anticancer drugs and related compounds with DNA. Coord Chem Rev 100: 293
Treskes M, Holwerda U, Klein I, Pinedo HM, Vijgh WJF van der (1991) The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol 42: 2125
Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, Pinedo HM, Vijgh WJF van der (1992) Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin/DNA adducts in vitro. Biochem Pharmacol (in press)
Treskes M, Boven E, Holwerda U, Pinedo HM, Vijgh WJF van der (1992) Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 (ethiofos) in the mouse. Cancer Res (in press)
Wasserman TH, Phillips TL, Ross G, Kane LJ (1981) Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 4: 3
Yuhas JM, Spellman JM, Jordan SW, Pardini MC, Afzal SMJ, Culo F (1980) Treatment of tumours with the combination of WR-2721 andcis-diamminedichloroplatinum(II) or cyclophosphamide. Br J Cancer 42: 574
Author information
Authors and Affiliations
Additional information
This study was financially supported by the Netherlands Cancer Fund (grant IKA 87-12) and by US Bioscience
Rights and permissions
About this article
Cite this article
Treskes, M., Holwerda, U., Nijtmans, L.G.J. et al. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278. Cancer Chemother. Pharmacol. 29, 467–470 (1992). https://doi.org/10.1007/BF00684849
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00684849